本帖最后由 老马 于 2012-1-13 21:20 编辑 1 j. M8 h, I+ \
! v: D, E) W3 T' ]7 k
爱必妥和阿瓦斯丁的比较
5 V$ K5 W) Y, n( ~6 _- V5 K
! C H f+ @! ], h) ghttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/9 J. [2 `/ P7 ?& V, O2 `3 H
g$ t4 K- T* j! @3 E& i
; J$ g2 d& C9 R- Whttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
' _" _! [# [3 l" Q3 }6 V! x& ~==================================================5 Q) i$ t2 {+ h
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL); q3 N1 K) Y: {- I+ ]/ }+ s
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.. g& \) H* t7 R
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' d2 k3 s5 h3 g3 V! T
|
显身卡
" R& X! ~7 z! r; [; K* p, e% h& C
